Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Dániel Deme, Bálint Ferenc Tamaskovics, Nizar Jammoul, Sándor Kovács, Emmanuel Oladunjoye Kayode, James W Grice, András Telekes
Introduction: The 21-gene analysis (OncotypeDX) is validated test for pT1-3, pN0-1 with hormone receptor (HR) positive and normal expression of human epidermal growth factor receptor-2 (HER2) breast cancer (BC) to determine the aggressiveness of the disease based on the calculation of Recurrence Score (RS). Methods: In this retrospective study the authors correlated pathological characteristics and Recurrence Score (RS) by traditional statistical methods and Observed Oriented Modeling (OOM) in a realistic cohort of BC patients...
2024: Pathology Oncology Research: POR
#2
JOURNAL ARTICLE
Jincong Q Freeman, Dezheng Huo
The Oncotype DX (ODX) assay predicts recurrence risk and demonstrates the benefits of adjuvant therapy in patients with early-stage, hormone receptor (HR)-positive/HER2-negative breast cancer. ODX uptake varies by patients' racial/ethnic backgrounds and socioeconomic status (SES). However, community-level variability remains unknown, and research regarding the association between testing status and receipt of adjuvant chemotherapy is limited. To fill these knowledge gaps, Van Alsten and colleagues found a 6% lower prevalence of ODX uptake among patients residing in high SES-deprived areas than among those residing in low SES-deprived areas...
May 1, 2024: Cancer Epidemiology, Biomarkers & Prevention
#3
JOURNAL ARTICLE
Robin Schaffar, Simone Benhamou, Pierre O Chappuis, Elisabetta Rapiti
PURPOSE: Breast cancer (BC) in women under 45 is rare yet often aggressive. We aim to analyze loco-regional recurrences (LR), distant recurrences (DR), second breast cancers, and mortality in young BC patients. METHODS: We enrolled 776 women with non-metastatic BC ≤45 years diagnosed from 1970 to 2012. Variables included age, family history, tumor stage/grade, and treatment. We used multivariate Cox regression and competing risk models. RESULTS: Among the participants, 37...
April 30, 2024: Breast Cancer Research and Treatment
#4
JOURNAL ARTICLE
Jai Min Ryu, Hyunjun Lee, Wonshik Han, Han-Byoel Lee, Sung Gwe Ahn, Hee Jeong Kim, Hyung Seok Park, Ji Soo Choi, Haeyoung Kim, Won Kyung Cho, Jeong Eon Lee
PURPOSE: The Avoid Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy (ASLAN) trial aims to demonstrate the oncologic safety of omitting axillary surgery in patients with excellent response after neoadjuvant chemotherapy (NACT) for early human epidermal growth factor 2 (HER2)-positive (+)/triple-negative breast cancer (TNBC) who have undergone breast-conserving surgery (BCS) and adjuvant radiotherapy. The ASLAN trial will provide crucial information that could change the procedure in highly selected patients undergoing axillary surgery after NACT...
April 2024: Journal of Breast Cancer
#5
JOURNAL ARTICLE
Kamran Roudini, Mehrzad Mirzania, Tahereh Yavari, Monireh Sadat Seyyedsalehi, Azin Nahvijou, Jayran Zebardast, Mina Saadat, Ahmad Khajeh-Mehrizi
BACKGROUND: Neoadjuvant chemotherapy (NCT) has become an increasingly popular approach in management of breast cancer (BC). This study was conducted to evaluate the pathologic response and 36-month recurrence and survival rates of patients with human epidermal growth factor receptor 2 (HER2)-negative BC treated with different NCT regimens. METHODS: A total of 163 female patients with HER2-negative BC who received NCT during 2017-2020 were identified from the Clinical Breast Cancer Registry of Iran and entered the study...
April 1, 2024: Archives of Iranian Medicine
#6
JOURNAL ARTICLE
Jiayu Ye, John M Baer, Douglas V Faget, Vasilios A Morikis, Qihao Ren, Anupama Melam, Ana Paula Delgado, Xianmin Luo, Satarupa Mullick Bagchi, Jad I Belle, Edward Campos, Michael Friedman, Deborah J Veis, Erik S Knudsen, Agnieszka K Witkiewicz, Scott Powers, Gregory D Longmore, David G DeNardo, Sheila A Stewart
UNLABELLED: The tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes distinct cancer-associated fibroblast (CAF) subtypes whose contribution to tumorigenesis remains unclear. Here, we identify a subset of myofibroblast CAFs (myCAF) that are senescent (senCAF) in mouse and human breast tumors. Utilizing the MMTV-PyMT;INK-ATTAC (INK) mouse model, we found that senCAF-secreted extracellular matrix specifically limits natural killer (NK) cell cytotoxicity to promote tumor growth...
April 17, 2024: Cancer Discovery
#7
JOURNAL ARTICLE
Jiayu Ye, John M Baer, Douglas V Faget, Vasilios A Morikis, Qihao Ren, Anupama Melam, Ana Paula Delgado, Xianmin Luo, Satarupa Mullick Bagchi, Jad I Belle, Edward Campos, Michael Friedman, Deborah J Veis, Erik S Knudsen, Agnieszka K Witkiewicz, Scott Powers, Gregory D Longmore, David G DeNardo, Sheila A Stewart
The tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes distinct cancer-associated fibroblast (CAF) subtypes whose contribution to tumorigenesis remains unclear. Here, we identify a subset of myofibroblast cancer associated fibroblasts (myCAF) that are senescent (senCAF) in mouse and human breast tumors. Utilizing the MMTV-PyMT;INK-ATTAC (INK) mouse model, we found that senCAF-secreted extracellular matrix specifically limits natural killer (NK) cell cytotoxicity to promote tumor growth...
April 29, 2024: Cancer Discovery
#8
REVIEW
Zhipu Niu, Jingyuan Wu, Qiancheng Zhao, Jinyu Zhang, Pengyu Zhang, Yiming Yang
Surgery, chemotherapy, and endocrine therapy have improved the overall survival and postoperative recurrence rates of Luminal A, Luminal B, and HER2-positive breast cancers but treatment modalities for triple-negative breast cancer (TNBC) with poor prognosis remain limited. The effective application of the rapidly developing chimeric antigen receptor (CAR)-T cell therapy in hematological tumors provides new ideas for the treatment of breast cancer. Choosing suitable and specific targets is crucial for applying CAR-T therapy for breast cancer treatment...
2024: Frontiers in Immunology
#9
JOURNAL ARTICLE
Akihiko Shimomura, Yasuaki Sagara, Ryo Koto, Masakazu Fujiwara, Yuka Kanemura, Hiroshi Kitagawa, Shigehira Saji
BACKGROUND: Anthracycline- and taxane-based chemotherapy regimens are established treatments for human epidermal growth factor receptor (HER)2-negative early-stage breast cancer with high risk of recurrence. This study examined the prevalence of these chemotherapy regimens as perioperative therapy, the patterns of retreatment, and factors influencing prescription choices in Japan. METHODS: This observational cohort study focused on high-risk early-stage breast cancer patients not undergoing anti-HER2 therapy, utilizing data from a hospital-based claims database in Japan spanning from April 2008 to September 2021...
April 29, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
#10
JOURNAL ARTICLE
Hisanori Kawamoto, Koichiro Tsugawa, Yuko Furuya, Kaori Sakamaki, Sayoko Kakimoto, Mina Kitajima, Mariko Nagai Takishita, Mizuho Tazo, Mari Hara Nakano, Takako Kuroda, Ayaka Shimo, Arata Shimo, Yasuyuki Kojima, Makiko Tsuzuki, Ai Motoyoshi, Ei Haku, Toru Nishikawa, Yoshihide Kanemaki, Hidefumi Mimura, Mamoru Fukuda
BACKGROUND: Ultrasound-guided percutaneous cryoablation (PCA) for early-stage breast cancer (ESBC) can be performed under local anesthesia in an outpatient clinic. This study continues a pilot stage to examine local control, safety, patient quality of life (QoL), satisfaction and cosmetic outcomes of cryoablation for ESBC. METHODS: PCA was performed under local anesthesia for patients with primary ESBC, followed by radiation and endocrine therapies. Oncologic outcomes were examined by imaging (mammography, ultrasound, MRI) at baseline and 1, 6, 12, 24, 36, and 60 months post-cryoablation...
April 27, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
#11
JOURNAL ARTICLE
S W M Lammers, M Meegdes, I J H Vriens, A C Voogd, L de Munck, T J A van Nijnatten, K B M I Keymeulen, V C G Tjan-Heijnen, S M E Geurts
BACKGROUND: Several factors may increase the risk of recurrence of patients diagnosed with hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC). We aim to determine the proportion of patients with high-risk HR+/HER2- BC within the total HR+/HER2- BC cohort and compare their systemic treatments and survival rates with those of patients with low- and intermediate-risk HR+/HER2- BC and triple-negative (TN) BC. PATIENTS AND METHODS: Women diagnosed with nonmetastatic invasive HR+/HER2- BC and TNBC in the Netherlands between 2011 and 2019 were identified from the Netherlands Cancer Registry...
April 26, 2024: ESMO Open
#12
JOURNAL ARTICLE
Samuel A Kareff, Asaad Trabolsi, Harris B Krause, Timothy Samec, Andrew Elliott, Estelamari Rodriguez, Coral Olazagasti, Dionysios C Watson, Matias A Bustos, Dave S B Hoon, Stephanie L Graff, Emmanuel S Antonarakis, Sanjay Goel, George Sledge, Gilberto Lopes
Tipifarnib is the only targeted therapy breakthrough for HRAS -mutant ( HRAS mt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of HRAS mt cancers are difficult to explore given the low frequency of HRAS mt. This study aims to understand the molecular co-alterations, immune profiles, and clinical outcomes of 524 HRAS mt solid tumors including urothelial carcinoma (UC), breast cancer (BC), non-small-cell lung cancer (NSCLC), melanoma, and HNSCC. HRAS mt was most common in UC (3...
April 19, 2024: Cancers
#13
JOURNAL ARTICLE
Dominik Dannehl, Alexandra von Au, Tobias Engler, Léa Louise Volmer, Raphael Gutsfeld, Johannes Felix Englisch, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Armin Bauer, Markus Wallwiener, Florin-Andrei Taran, Diethelm Wallwiener, Sara Yvonne Brucker, Stephanie Wallwiener, Andreas Daniel Hartkopf, Tjeerd Maarten Hein Dijkstra
Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide. This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer disease model. The study included 27,869 female breast cancer patients and 55,738 age-matched controls, analyzing data from 2010 to 2020. Three distinct breast cancer stages were analyzed: Stage A (early breast cancer without lymph node involvement), Stage B (early breast cancer with lymph node involvement), and Stage C (primary distant metastatic breast cancer)...
April 13, 2024: Cancers
#14
REVIEW
Savannah R Brown, Emilie E Vomhof-DeKrey
Breast cancer receives the most funding when compared to any other cancer type, according to a global study conducted by The Lancet . Nevertheless, this malignancy remains the most diagnosed cancer among women and relies heavily on a neoadjuvant treatment regimen of chemotherapy and targeted therapy. After standard treatment, 25-30% of breast cancer patients still develop disease recurrence and must undergo cytoreductive debulking surgery followed by intensive chemotherapy. An array of targeted therapies are currently being utilized and developed to alleviate negative side effects, eradicate cancer growth, and diminish disease recurrence...
April 18, 2024: Biomedicines
#15
JOURNAL ARTICLE
Valentina E Bounous, Carola Minella, Luca Fuso, Silvia Actis, Greta Petroni, Luca G Sgrò, Martina Borghese, Nicoletta Tomasi Cont, Riccardo Ponzone, Annamaria Ferrero
BACKGROUND: pregnancy-associated breast cancer (PABC) affects one in 3000 pregnancies, often presenting with aggressive features. METHODS: We retrospectively evaluated a cohort of 282 young BC patients (≤45 years old) treated between 1995 and 2019, dividing them into three groups: nulliparous women, women with PABC (diagnosed within 2 years since last pregnancy) and women with BC diagnosed > 2 years since last pregnancy. This last group was further stratified according to the time between pregnancy and BC...
April 19, 2024: Current Oncology
#16
JOURNAL ARTICLE
M Bradbury, M F Savard, C Stober, L Clemons, M Clemons, J Hilton, G Pond, L Vandermeer, S F McGee
PURPOSE: Despite previous studies proposing shorter durations of anti-HER2 therapy for selected patients with HER2-positive early breast cancer (EBC), 12-months remains standard of care. A survey was performed to assess patient perspectives and willingness to participate in studies evaluating shorter durations of anti-HER2 therapy. METHODS: Patients with HER2-positive EBC completing or having previously completed anti-HER2 therapy, were recruited by healthcare professionals at The Ottawa Hospital Cancer Centre to participate in an anonymous online survey...
April 25, 2024: Breast Cancer Research and Treatment
#17
JOURNAL ARTICLE
Giacomo Montagna, Mary M Mrdutt, Susie X Sun, Callie Hlavin, Emilia J Diego, Stephanie M Wong, Andrea V Barrio, Astrid Botty van den Bruele, Neslihan Cabioglu, Varadan Sevilimedu, Laura H Rosenberger, E Shelley Hwang, Abigail Ingham, Bärbel Papassotiropoulos, Bich Doan Nguyen-Sträuli, Christian Kurzeder, Danilo Díaz Aybar, Denise Vorburger, Dieter Michael Matlac, Edvin Ostapenko, Fabian Riedel, Florian Fitzal, Francesco Meani, Franziska Fick, Jacqueline Sagasser, Jörg Heil, Hasan Karanlik, Konstantin J Dedes, Laszlo Romics, Maggie Banys-Paluchowski, Mahmut Muslumanoglu, Maria Del Rosario Cueva Perez, Marcelo Chávez Díaz, Martin Heidinger, Mathias K Fehr, Mattea Reinisch, Mustafa Tukenmez, Nadia Maggi, Nicola Rocco, Nina Ditsch, Oreste Davide Gentilini, Regis R Paulinelli, Sebastián Solé Zarhi, Sherko Kuemmel, Simona Bruzas, Simona di Lascio, Tamara K Parissenti, Tanya L Hoskin, Uwe Güth, Valentina Ovalle, Christoph Tausch, Henry M Kuerer, Abigail S Caudle, Jean-Francois Boileau, Judy C Boughey, Thorsten Kühn, Monica Morrow, Walter P Weber
IMPORTANCE: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown. OBJECTIVE: To investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node...
April 25, 2024: JAMA Oncology
#18
JOURNAL ARTICLE
Srinivas Veerla, Johan Staaf
Kataegis is a hypermutation phenomenon characterized by localized clusters of single base pair substitution (SBS) reported in multiple cancer types. Despite a high frequency in breast cancer, large-scale analyses of kataegis patterns and associations with clinicopathological and molecular variables in established breast cancer subgroups are lacking. Therefore, WGS profiled primary breast cancers (n = 791) with associated clinical and molecular data layers, like RNA-sequencing data, were analyzed for kataegis frequency, recurrence, and associations with genomic contexts and functional elements, transcriptional patterns, driver alterations, homologous recombination deficiency (HRD), and prognosis in tumor subgroups defined by ER, PR, and HER2/ERBB2 status...
April 24, 2024: NPJ Breast Cancer
#19
REVIEW
Yusuke Matoba, Kyle M Devins, Lara Milane, William B Manning, Varvara Mazina, Oladapo O Yeku, Bo R Rueda
Although many recent advancements have been made in women's health, perhaps one of the most neglected areas of research is the diagnosis and treatment of high-grade endometrial cancer (EnCa). The molecular classification of EnCa in concert with histology was a major step forward. The integration of profiling for mismatch repair deficiency and Human Epidermal Growth Factor 2 (HER2) overexpression, can further inform treatment options, especially for drug resistant recurrent disease. Recent early phase trials suggest that regardless of subtype, combination therapy with agents that have distinct mechanisms of action is a fruitful approach to the treatment of high-grade EnCa...
April 24, 2024: Reproductive Sciences
#20
JOURNAL ARTICLE
Makiko Go, Michio Kimura, Shiori Yamada, Eiseki Usami, Yoshihiro Noguchi, Tomoaki Yoshimura
Background : Appropriate adverse event (AE) management and maintenance of therapeutic intensity are necessary to achieve therapeutic benefits of CDK4/6 inhibitors (palbociclib and abemaciclib) in hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer. Objective : This study was aimed at clarifying the effect of AEs associated with palbociclib and abemaciclib on treatment. Methods : A total of 62 and 49 patients were prescribed palbociclib and abemaciclib, respectively, at our hospital from January 1, 2018 to June 30, 2023...
April 23, 2024: Journal of Pharmacy Practice
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
